The stock faces near-term delisting risk and severe operational contraction. Watch for a potential reverse stock split to regain Nasdaq compliance and any partnership announcements for the paused heme program. The pivot to early-stage solid tumor candidates is high-risk and likely years from value inflection. Traders should expect continued volatility and potential further downside.
Drugs in focus
TCRX drug pipeline →TSC-101
▼ Bearish Named in this 8-K- Impact
- Phase
- Phase 3 (paused)
- Time to market
- Uncertain. The Phase 3 trial is paused due to insufficient capital, and the company is seeking a partner to continue development. Even if partnered, a pivotal trial would need to complete before any regulatory filing, putting potential approval years away.
- Next catalyst
- None dated
What to watchTSC-101's development is paused, and the stock's fate hinges entirely on whether TScan can secure a partnership for the heme program. Without a partner, the Phase 3 trial will not resume and the program may be abandoned. The company's focus has shifted to preclinical solid tumor candidates, which are years from clinical data. Monitor for partnership announcements or a potential sale of the heme assets.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 2 $0.3810entry
- T+1 · 3mo ago −2.62%α −3.67% · $0.3710
- T+5 · 2mo ago −16.56%α −15.60% · $0.3179
- T+20 · 7w ago −17.32%α −17.24% · $0.3150
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TScan Therapeutics announced a drastic strategic reorganization: a 75% workforce reduction, termination of its CFO and CMO, and a pause on its lead heme malignancy program (Phase 3 ALLOHA-2) due to capital constraints. The company will focus on early-stage in vivo solid tumor candidates (PRAME and MAGE-A4) and expects cumulative cost savings of $55M through 2027, extending cash runway into Q4 2027. Simultaneously, it received a Nasdaq minimum bid price deficiency notice, creating delisting risk. The combination of severe restructuring, executive departures, and delisting notice signals acute financial distress.
Key Facts
- Workforce reduction of approximately 75% (Strategic Reorganization).
- Expected restructuring charges of ~$4.1 million in employee-related costs.
- CFO Jason Amello and CMO Chrystal Louis terminated; CEO Gavin MacBeath assumes principal financial and accounting officer duties.
- Received Nasdaq deficiency notice for minimum bid price non-compliance; 180-day cure period until February 23, 2027.
- Paused further enrollment in Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital; 7 patients already enrolled on treatment arm.
- Strategic refocus on in vivo solid tumor program: two candidates (PRAME and MAGE-A4) advanced to IND-enabling studies.
- Cumulative cost savings of $55.0 million expected through end of 2027.
- Cash, cash equivalents and marketable securities as of June 30, 2026 expected to fund operations into Q4 2027.
Financial Impact
Restructuring charges of ~$4.1M; cumulative cost savings of $55M through 2027; cash runway extended into Q4 2027.
Risk Factors
- Failure to regain Nasdaq minimum bid price compliance leading to delisting.
- Inability to secure strategic partnerships for heme or autoimmune programs.
- Clinical or regulatory setbacks in the early-stage solid tumor program.
- Further cash burn or need for dilutive financing before reaching milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-379343 |
| Document: d309786dex992.htm | 0001193125-26-379343 |
| Document: d309786dex991.htm | 0001193125-26-379343 |
| Document: 0001193125-26-379343-index-headers.html | 0001193125-26-379343 |
| Document: 0001193125-26-379343-index.html | 0001193125-26-379343 |
| Document: 0001193125-26-379343.txt | 0001193125-26-379343 |
Track record
15 reports on TCRX
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
- Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
- Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
- Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
- Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
- Sep 2, 202610w ago 8-K Bearish 7/10 Viewing Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
- Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
- Aug 12, 202613w ago 8-K Bearish 6/10 No price data
- Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers